BiCNU supply shortage
Executive Summary
Bristol-Myers Squibb announced Oct. 24 its supply difficulties with BiCNU (carmustine injection) are now a shortage; earlier the drug maker reported that it had a supply outage of the palliative cancer product ("1The Pink Sheet" Oct. 10, 2005, In Brief). The shortage is due to batches produced by a third-party supplier that needed additional assessment. Bristol has begun distributing a limited amount of the product...
You may also be interested in...
BiCNU supply shortage
Bristol-Myers Squibb is experiencing a supply outage of BiCNU (carmustine injection) chemotherapy, the drug maker reports Oct. 6. Bristol has not confirmed an availability date for the product, but says it is working to resolve the outage. The company is encouraging physicians and health care providers to use alternative treatments when possible. Supply issues due to production delays also occurred in May. BiCNU is indicated for palliative therapy in the treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.